Health Canada approves ZEPBOUND® as the first-ever obstructive sleep apnea medication in Canada for adults living with obesity
Health Canada has approved Eli Lilly's ZEPBOUND for the treatment of obstructive sleep apnea in adults with obesity. This marks the first medication approved in Canada specifically for this indication, intended for use alongside diet and exercise.
Why it matters
This approval provides a new medical intervention for a common, serious sleep disorder, potentially impacting public health outcomes for Canadians living with obesity.
TORONTO , June 16, 2026 /CNW/ - Eli Lilly Canada announced today that Health Canada has approved ZEPBOUND® (tirzepatide injection) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity (BMI 30 kg/m 2 or greater), to be used in combination with a reduced-calorie diet and increased physical activity. ZEPBOUND® is the first medication approved in Canada for this indication, offering a new option for people living with a serious sleep-related breathing disorder that is closely linked with obesity.
The article reports on a regulatory approval based on medical data without subjective framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in